GlassScriptPhysician profile
Leonid Iskhakov
NPI 1700031770
$7,147.88
in general payments reported to CMS, 2019-2025
39 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,502 · 2022: $1,557 · 2023: $1,022 · 2024: $1,201 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,089.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,904.41 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $731.80 | 2022-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $591.77 | 2021-2025 | |
| Allergan, INC. | $570.72 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $461.96 | 2021-2025 | Ajovy, Austedo, Austedo Xr |
| Genzyme Corporation | $310.61 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $290.75 | 2021-2025 | Ztlido |
| Axsome Therapeutics, INC. | $257.67 | 2025 | Symbravo, Auvelity |
| Ipsen Biopharmaceuticals, INC | $243.66 | 2023-2025 | Dysport |
| Depuy Synthes Sales INC. | $236.34 | 2023 | Orthovisc, Monovisc |
| Amgen INC. | $197.16 | 2021-2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $153.78 | 2022 | |
| Novartis Pharmaceuticals Corporation | $118.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $116.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.08 | 2024-2025 | Xifaxan, Trulance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $96.73 | 2021-2025 | Vyepti |
| Averitas Pharma INC. | $80.38 | 2024-2025 | Qutenza |
| Xeris Pharmaceuticals, INC. | $76.54 | 2024-2025 | Gvoke Hypopen |
| Ardelyx, INC. | $50.15 | 2024 | Ibsrela |
| Lilly USA, LLC | $49.36 | 2024 | Emgality |
| W. L. Gore & Associates, INC. | $46.74 | 2021 | |
| Eisai INC. | $43.05 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $38.50 | 2021 | |
| Cequr Corporation | $33.09 | 2024 | Cequr Simplicity |
| Mylan Specialty L.P. | $29.32 | 2023 | Yupelri |
| Amneal Pharmaceuticals LLC | $28.14 | 2025 | Crexont |
| Verona Pharma, INC. | $24.76 | 2025 | Ohtuvayre |
| Alnylam Pharmaceuticals INC. | $24.17 | 2024 | Amvuttra |
| Ucb, INC. | $24.08 | 2022 | |
| Avanir Pharmaceuticals, INC. | $23.70 | 2022 | |
| Nevro Corp. | $23.48 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.26 | 2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $23.04 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.85 | 2021 | |
| Harmony Biosciences LLC | $22.01 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.15 | 2025 | Ponvory |
| Biogen, INC. | $19.73 | 2024 | Leqembi |
| Genentech USA, INC. | $18.19 | 2021 | |
| Ibsa Pharma INC. | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Iskhakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.